clinical trial · NCT05824585
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lymphoma, Non-HodgkinDZD8586
brief summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
started
May 15, 2023
primary completion
Jun 30, 2025
completion
Jun 30, 2025
last updated
Jul 2, 2026
official title
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol